Praxis Precision Medicines (PRAX) Common Equity (2019 - 2026)

Praxis Precision Medicines' Common Equity history runs 8 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 221.02% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 221.02% YoY), while the FY2025 annual figure was $878.1 million, up 97.13% from the prior year.
• Common Equity for Q1 2026 stood at $1.4 billion, up from $878.1 million in the prior quarter.
• The five-year high for Common Equity was $1.4 billion in Q1 2026, with the low at $64.5 million in Q1 2023.
• The 5-year median for Common Equity is $229.7 million (2024), against an average of $340.6 million.
• The sharpest annual moves came in 2022 and 2024: Common Equity sank 69.66% in 2022, then jumped 539.38% in 2024.
• Praxis Precision Medicines' Common Equity stood at $76.1 million in 2022, then decreased by 8.46% to $69.7 million in 2023, then surged by 539.38% to $445.4 million in 2024, then jumped by 97.13% to $878.1 million in 2025, then surged by 60.56% to $1.4 billion in 2026.
• Business Quant data shows PRAX's Common Equity at $1.4 billion in Q1 2026, $878.1 million in Q4 2025, and $343.5 million in Q3 2025.